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A B S T R A C T
Purpose
Diffuse intrinsic pontine glioma (DIPG) is a brainstemmalignancy with a median survival of, 1 year.
The International and European Society for Pediatric Oncology DIPG Registries collaborated to
compare clinical, radiologic, and histomolecular characteristics between short-term survivors (STSs)
and long-term survivors (LTSs).
Materials and Methods
Data abstracted from registry databases included patients from North America, Australia, Germany,
Austria, Switzerland, the Netherlands, Italy, France, the United Kingdom, and Croatia.
Results
Among 1,130 pediatric and young adults with radiographically conﬁrmed DIPG, 122 (11%) were
excluded. Of the 1,008 remaining patients, 101 (10%) were LTSs (survival$ 2 years). Median survival
time was 11 months (interquartile range, 7.5 to 16 months), and 1-, 2-, 3-, 4-, and 5-year survival rates
were 42.3% (95%CI, 38.1% to 44.1%), 9.6% (95%CI, 7.8% to 11.3%), 4.3% (95%CI, 3.2% to 5.8%),
3.2% (95% CI, 2.4% to 4.6%), and 2.2% (95% CI, 1.4% to 3.4%), respectively. LTSs, compared with
STSs, more commonly presented at age, 3 or. 10 years (11% v 3% and 33% v 23%, respectively;
P, .001) and with longer symptom duration (P, .001). STSs, compared with LTSs, more commonly
presentedwith cranial nerve palsy (83% v 73%, respectively;P= .008), ring enhancement (38% v 23%,
respectively;P= .007), necrosis (42% v 26%, respectively;P= .009), and extrapontine extension (92% v
86%, respectively; P = .04). LTSs more commonly received systemic therapy at diagnosis (88% v
75% for STSs; P = .005). Biopsies and autopsies were performed in 299 patients (30%) and 77
patients (10%), respectively; 181 tumors (48%) were molecularly characterized. LTSs were more
likely to harbor a HIST1H3B mutation (odds ratio, 1.28; 95% CI, 1.1 to 1.5; P = .002).
Conclusion
We report clinical, radiologic, and molecular factors that correlate with survival in children and young
adults with DIPG, which are important for risk stratiﬁcation in future clinical trials.
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INTRODUCTION
Diffuse intrinsic pontine glioma (DIPG) is a malignant brainstem
tumor of childhood for which median survival is , 1 year.1 Long-
term survival, historically deﬁned as overall survival (OS) . 2
years, is reported in , 10% of patients.1 Characteristics associated
with longer survival include younger age, longer symptom latency,
and absent ring enhancement on diagnostic magnetic resonance
imaging.1,2 Up to 90% of DIPGs harbor a pathognomonic point
mutation inH3F3A (65% of tumors) orHIST1H3B (25% of tumors);
the latter seems to confer longer survival. Ten percent of patients
have a histone 3 wild-type tumor.3
Involved-ﬁeld radiation therapy (RT) remains standard of care
but confers only a 3- to 4-month survival advantage. Beneﬁt from
neoadjuvant4 or adjuvant2,5 chemotherapy has not been consistently
conﬁrmed in prospective trials.
The rarity and inconsistent classiﬁcation of DIPG, an imaging-
based diagnosis, have long hampered cross-cohort comparisons. The
primary aim of this multinational collaboration between the In-
ternational DIPG Registry (IDIPGR) and European Society for
Pediatric Oncology DIPG Registry (SIOPE-DIPGR)6,7 was to deﬁne
clinical, radiologic, histologic, and molecular factors associated with
short- and long-term survival in the largest cohort of centrally
reviewed DIPGs to date.
MATERIALS AND METHODS
Study Population
The study was approved by the institutional review board at Cin-
cinnati Children’s Hospital Medical Center and included 1,130 patients
with radiographically conﬁrmed DIPG diagnosed from 1990 to 2015.
IDIPGR patients (n = 409) were age 0 to 27 years from the United States,
Canada, and Australia. SIOPE-DIPGR patients (n = 721) were age 0 to 21
years from the Netherlands, Germany, Austria, Switzerland, Italy, France,
the United Kingdom, and Croatia. Patients were referred to the registries as
previously described.6,7 Exclusion criteria are listed in Figure 1. No patients
with neuroﬁbromatosis type 1 were included.
Clinical Variables
Clinical data were abstracted (J.B., B.C., S.E.M.V.v.Z., and N.C.) using
standardized case report forms. Cerebellar signs included dysmetria,
ataxia, dysarthria, or nystagmus. Pyramidal tract signs included mono-,
hemi-, or quadriparesis; hyperreﬂexia; or positive Babinski sign. Because
over survival (OS), deﬁned as the time from diagnosis to death or last
follow-up, is regarded as the most reliable outcome variable for DIPG,
progression-free survival (PFS) was not reported. Short-term survivors
(STSs), long-term survivors (LTSs), and very long–term survivors (VLTSs)
had OS times of , 24, $ 24, and $ 60 months, respectively. Two LTSs
(patients DIPG-0016 and DIPG-0081) lost to follow-up at our data cutoff
(January 1, 2017) were included in primary statistical analyses.
Radiologic Variables
Anonymized diagnostic magnetic resonance imaging was centrally
reviewed (M.W., B.B., E.S., R.C., J.L., and B.J.) and classiﬁed as typical or
unlikely DIPG; the latter were excluded. Typical DIPGs arose from and
diffusely involved $ 50% of the pons. Exclusionary features included
focally exophytic morphology, marked diffusion restriction, or second-
ary brainstem involvement by a tumor centered elsewhere in the brain or spine.
Diagnostic imaging from all LTSs and 10% of STSs was cross-validated by
a neuroradiologist from the other registry. Metastatic disease, deﬁned as
noncontiguous tumor in the brain or spine, was reported by individual
sites but not centrally reviewed.
Histopathologic and Molecular Variables
Histology was deﬁned according to 2007 WHO criteria8; based on
availability of tissue in the registries, 61 tumor specimens were centrally
reviewed (C.F. and C.H.). Databases were queried for common genomic
alterations in DIPG. Histone mutations were assessed by Sanger sequencing,
whole-exome sequencing, or whole-genome sequencing, polymerase chain
reaction, or immunohistochemistry to detect H3K27M-mutant protein or
H3K27 trimethylation (H3K27me3). Mutations inH3F3A (H3.3 K27M) or
HIST1H3B (H3.1 K27M) were considered mutually exclusive even if both
were not evaluated.
Statistical Analyses
Patient characteristics were summarized using medians and ranges or
frequencies and percentages. Univariable analyses were performed using
the Fisher’s exact test or Wilcoxon rank sum test. Multivariable logistic
regression was performed on variables with , 15% missing data and
univariable P , .1; however, transverse tumor dimension was excluded as
a result of high correlation with craniocaudal dimension. For subgroup
analyses, multivariable logistic regression models were used to determine
subgroup signiﬁcance and adjusted for confounding factors. Survival was
estimated using the Kaplan-Meier method. Statistical evaluation was per-
formed using R (Version 3.1.3). P , .05 was considered signiﬁcant.
RESULTS
Survival
A total of 1,008 patients met inclusion criteria (IDIPGR, n =
374; SIOPE-DIPGR, n = 634). Median survival time was 11months
Radiographically-confirmed DIPGs
 (N = 1,130)
Patients with DIPGs included
 (n = 1,008)
Diagnosed < 2 years from data cutoff
(n = 27)
Survival status unknown
(n = 39)
Treatment unknown
(n = 5)
No intent to treat at diagnosis
(n = 38)
Less than 50% pontine involvement
(n = 5)
WHO grade 1 glioma
(n = 3)
Nonglioma histology
(n = 5)
Fig 1. Flowchart of patients excluded from this study. DIPG, diffuse intrinsic
pontine glioma.
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(interquartile range, 7.5 to 16 months), and 1-, 2-, 3-, 4-, and 5-year
OS rates were 42.3% (95% CI, 38.1% to 44.1%), 9.6% (95% CI,
7.8% to 11.3%), 4.3% (95% CI, 3.2% to 5.8%), 3.2% (95% CI,
2.4% to 4.6%), and 2.2% (95% CI, 1.4% to 3.4%), respectively.
Characteristics of 101 LTSs (10%) and 16 VLTSs (1.6%) are shown
in Figure 2 and Appendix Figure A1 (online only), respectively. Kaplan-
Meier survival analyses for age, symptom duration, systemic therapy,
histology, and molecular status are shown in Figure 3.
Clinical Presentation
Median age was 6.8 years (range, 0 to 26.8 years); 4% of patients
were age , 3 years at diagnosis. Of patients with available data, 755
(82%) of 917, 468 (51%) of 915, and 567 (62%) of 920 patients
presented with one or more cranial nerve (CN) palsy, pyramidal
tract, or cerebellar sign, respectively. On univariable analysis (Table 1),
LTSs were more likely to be age , 3 years (28% v 3% of STSs) or
. 10 years (33% v 23% of STSs; P, .001) and had longer symptom
duration at diagnosis. LTSs were less likely to present with CN palsy
(72% v 83% of STSs; P = .008). Multivariable analyses (Table 2)
conﬁrmed association of age and symptom duration with long-term
survival but failed to associate CN palsy with short-term survival.
Therapy
Thirty-eight patients (3%) who did not receive therapy at
diagnosis (Appendix Fig A2A, online only) were excluded. Un-
treated patients were more often, 3 years old at diagnosis. Eleven
patients underwent biopsy or autopsy. At progression, one patient
received chemotherapy; no patients received RT. Median OS of
untreated patients was 1month (range, 0 to 135months). Two patients
were LTSs (both infants), including one who was alive 135 months
after diagnosis (Appendix Fig A2B, online only).
The status of RT and systemic therapy was known for 968
patients; 721 patients (74%) received both RT and systemic therapy,
231 patients (24%) received RTalone, and 16 patients (2%) received
systemic therapy alone. In univariable and multivariable analyses,
LTSs more commonly received systemic therapy at diagnosis (88% v
75% for STSs; P = .005; odds ratio [OR], 3; 95% CI, 1.46 to 7.3;
P = .01). Systemic therapy type was known for 702 patients (70%);
350 patients (50%) received cytotoxic therapy only, 193 patients
(27%) received targeted therapy only, and 159 patients (23%)
received both cytotoxic and targeted. On univariable analysis, type
of targeted therapy yielded no survival difference (Table 1).
However, multivariable logistic regression adjusted for age and
symptomdurationdemonstrated greater odds of long-term survivalwith
use of an epidermal growth factor receptor (EGFR) inhibitor (OR, 2.32;
95%CI, 1.1 to 4.82; P= .03) or bevacizumab (OR, 2.67; 95%CI, 1.09 to
6.55; P = .03), an anti–vascular endothelial growth factor (VEGF) an-
tibody, at diagnosis (Table 2). Seventy-two patients (7%) underwent
reirradiation at ﬁrst or subsequent progression (as reported by individual
sites). The rate ofﬁrst progression recordedwithin 1 year of diagnosiswas
signiﬁcantly lower in patients who underwent reirradiation compared
with patients who did not (74% v 88%, respectively; P = .007).
Imaging
Table 1 lists diagnostic imaging characteristics. STSs dem-
onstrated larger craniocaudal tumor dimension (43 v 40 mm for
LTSs; P = .04) and higher rates of extrapontine extension (92% v
85% for LTSs; P= .04), tumor necrosis (45% v 26% for LTSs;P= .009),
and ring enhancement (38% v 23% for LTSs; P = .007). Metastatic
disease at diagnosis was reported in 18 STSs (2%) and no LTSs.
Histology and Molecular Characteristics
More SIOPE-DIPGR patients (39%) than IDIPGR patients
(14%) underwent biopsy, and more IDIPGR patients (16%) than
SIOPE-DIPGR patients (4%) underwent autopsy (Appendix Table
A1, online only). LTSs from both registries were more often
biopsied than STSs (38% v 28%, respectively; P = .04). Histology
and WHO grade were known for 288 biopsy and 76 autopsy
samples. WHO grade did not inﬂuence survival. Biopsy specimens
included glioblastoma multiforme (GBM; n = 80), anaplastic
astrocytoma (n = 76), anaplastic oligodendroglioma (n = 10),
diffuse astrocytoma (n = 37), ﬁbrillary astrocytoma (n = 4), oligo-
dendroglioma (n = 2), low-grade astrocytoma (n = 8), and unknown
(n = 71). Histology of autopsy tissue included GBM (n = 48),
anaplastic astrocytoma (n = 12), diffuse astrocytoma (n = 3), and
unknown (n = 13).
Of 376 patients fromwhom tissue was obtained, genomic data
were available for 181 (48%) of patients (18% of the entire cohort;
Data Supplement), including 21 LTSs (Fig 4). Global molecular
assessment was undertaken for 44 patients (whole-genome se-
quencing, n = 16; whole-exome sequencing, n = 25; 450k
methylation array, n = 3), whereas 98 patients underwent limited
genomic sequencing (Sanger, n = 80; other targeted platform,
n = 18), and 36 patients underwent immunohistochemistry alone.
H3.1 K27M was associated with longer median OS (15 months)
and long-term survival in multivariable analysis (OR, 1.28; 95%
CI, 1.1 to 1.5; P = .002). In contrast, H3.3 K27M was associated
with short-term survival (OR, 0.88; 95% CI, 0.78 to 0.99; P = .04;
median survival, 10.4 months). Patients with H3 wild-type tumors
(n = 26) had a median OS of 10.5 months. WHO grade did not
correlate with histone mutation status. TP53 and ACVR1 muta-
tions were not associated with survival. Of the 50 patients age. 10
years at diagnosis, who as a group demonstrated higher likelihood
of long-term survival, 38 (78%) harbored H3.3 K27M, nine (18%)
were H3 wild-type, and only three (6%) had H3.1 K27M.
DISCUSSION
This study conﬁrms the relevance of some previously reported
survival-associated factors in patients with DIPG and offers unique
insight into 101 LTSs (including 16 VLTSs). Median survival for all
1,008 patients was 11 months.1,5 Median survival times of LTSs and
VLTSs were 33 months (range, 24 to 156 months) and 78 months
(range, 60 to 156 months), respectively. Of 16 surviving patients,
two were lost to follow-up but were LTSs at the time of last contact
(patients DIPG-0016 and DIPG-0081; OS, 33 and 36 months). The
2-year OS rate of 9.6% in this study was consistent with large
retrospective studies2,5 that reported 9.2% and 9% 2-year OS rates
in 153 and 316 patients with DIPG, respectively. The 1-year OS rate
in our study (42.3%) is comparable to that reported by Hassan
et al9 in a meta-analysis of 2,336 pediatric patients with high-grade
brainstem glioma (41%); however, the 2- and 3-year OS rates of
15.3% (95% CI, 12% to 20%) and 7.3% (95% CI, 5.2% to 10%) in
jco.org © 2018 by American Society of Clinical Oncology 3
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Deceased
Fig 2. Clinical, histologic, and molecular character-
istics of long-term survivors of diffuse intrinsic pontine
glioma. Bev, bevacizumab; CN, cranial nerve; CRO,
Croatia; DIPG, International DIPG Registry; EGFR,
epidermal growth factor receptor; FR, France; GER,
Germany, Switzerland, Austria; GOSH, Great Ormond
Street Hospital; HDAC, histone deacetylase inhibitor;
IT, Italy; LFU, last follow-up; mTOR, mammalian target
of rapamycin inhibitor; NETH, the Netherlands; OS,
overall survival; Re-RT, reirradiation; RT, radiation therapy;
UK, United Kingdom; Unkn, unknown.
4 © 2018 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Hoffman et al
Downloaded from ascopubs.org by INSTITUTE CANCER RESEARCH on May 14, 2018 from 193.062.218.079
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
Symptom
Duration
Systemic
Therapy at
Diagnosis
Age at
Diagnosis
Histone
Status
WHO
Grade
0 929 978 1,026 163 227
39 41 42 8 13
30 31 32 5 11
19 19 19 2 5
418 452 469 74 113
89 97 101 19 29
1
2
3
4
5
< .001 < .001 < .001 .13 .0064P value
E
5
H3.3
67%
H3.1
18%
WT
15%
0
0.2
0.4
0.6
OS
 (p
ro
ba
bi
lit
y)
Time Post Diagnosis (years)
0.8
1.0
1 2 3 4
H3.1 K27M
H3.3 K27M
WT
A
< 3 years
4%
3-10 years
72%
> 10 years
24%
0
0.2
0.4
0.6
OS
 (p
ro
ba
bi
lit
y)
Time Post Diagnosis (years)
0.8
1.0
1 2 3 4 5
< 3 years
3-10 years
> 10 years
B
< 6
67%
6-12
19%
12-24
8%
> 24
6%
0
0.2
0.4
0.6
OS
 (p
ro
ba
bi
lit
y)
Time Post Diagnosis (years)
0.8
1.0
1 2 3 4 5
< 6 weeks
6-12 weeks
> 24 weeks
12-24 weeks
C
Systemic therapy
76%
No systemic therapy
24%
0
0.2
0.4
0.6
OS
 (p
ro
ba
bi
lit
y)
Time Post Diagnosis (years)
0.8
1.0
1 2 3 4 5
No systemic therapy
Systemic therapy
D
Grade 2
24%
Grade 3
39%
Grade 4
37%
0
0.2
0.4
0.6
OS
 (p
ro
ba
bi
lit
y)
Time Post Diagnosis (years)
0.8
1.0
1 2 3 4 5
2
3
4
Time
(years)
No. at risk:
Fig 3. Kaplan-Meier curves representing overall survival (OS) based on (A) patient age (years), (B) symptom duration (weeks), (C) systemic therapy at diagnosis, (D)WHO
grade, or (E) histone status. WT, wild type.
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their study were higher than those in our study (9.6% and 4.3%,
respectively), likely reﬂecting the heterogeneity of their cohort,
some whom may not have true DIPGs.
Previously, 43 VLTSs had been reported in the literature.1,10-15
In Appendix Figure A1, we compare the characteristics of 22
previously published VLTSs to our 16 VLTSs, including eight
(0.02% of the total cohort) who are alive with a median follow-up
time of 6.5 years (range, 5 to 13 years). Our 5-year OS rate of 2.3%
is comparable to the rate of 2.6% reported by Jackson et al1 in 191
patients with DIPG; however, two of their ﬁve VLTSs would have
been excluded from our study for atypical magnetic resonance
imaging features. Freeman et al12 reported nine VLTSs (6.9%)
among 130 patients with DIPG treated with hyperfractionated
RT (Pediatric Oncology Group 8495 trial), although only four of
these patients (3%) would have met inclusion criteria in our
study.
Age , 3 or . 10 years, longer symptom latency, lack of CN
palsy, and systemic therapy at diagnosis were predictors of long-
term survival. Of 41 patients age, 3 years at diagnosis, 36 received
ﬁrst-line RT with or without systemic therapy and ﬁve received
systemic therapy alone. Although median OS for children age , 3
years (11 months) was the same as the entire cohort, a greater
proportion was LTSs or VLTSs. Other studies have reported similar
ﬁndings.1,2,5,16 Broniscer et al17 described 10 DIPG patients age
, 3 years who received RTwith or without chemotherapy (n = 8)
or chemotherapy only (n= 2) at diagnosis (n= 6) or progression (n= 4).
Five patients (50%) were LTSs, including one treated without RT.
Wagner et al5 similarly reported higher median survival in 13
Table 1. Results of Univariable Analyses Comparing Clinical, Radiologic, and
Histologic Characteristics of Long- and Short-Term Survivors of Diffuse
Intrinsic Pontine Glioma
Characteristic LTSs (n = 101) STSs (n = 907) P
Clinical
Registry, No. (%) .39
International 33 (9) 341 (91)
SIOPE 68 (11) 566 (89)
Sex, No. (%) .46
Male 51 (50) 420 (46)
Female 50 (50) 485 (54)
Race, No. (%) .43
African 4 (9) 43 (12)
Asian 2 (4) 14 (4)
White 36 (80) 237 (69)
Other 3 (7) 50 (15)
Median age, years (range) 7.2 (1.9-26.8) 6.8 (0-26.5) .61
Age, years, No. (%) , .001
, 3 11 (11) 29 (3)
3-10 57 (56) 668 (74)
. 10 33 (33) 205(23)
Symptom duration, weeks, No. (%) , .001
, 6 45 (51) 564 (69)
6-12 19 (21) 156 (19)
12-24 11 (12) 62 (8)
. 24 14 (16) 35 (4)
Symptoms at diagnosis, No. (%)
Cranial nerve palsy .008
Yes 63 (73) 692 (83)
No 25 (27) 137 (17)
Pyramidal tract sign .5
Yes 39 (44) 429 (52)
No 50 (56) 397 (48)
Cerebellar sign .08
Yes 46 (53) 521 (63)
No 41 (47) 312 (37)
CSF diversion, No. (%) 1.00
Yes 22 (22) 196 (22)
No 79 (78) 709 (78)
Systemic therapy at diagnosis, No. (%) .005
Yes 85 (88) 644 (75)
No 12 (12) 214 (25)
Category of systemic therapy, No. (%) .07
Cytotoxic chemotherapy 36 (44) 314 (51)
Targeted chemotherapy 19 (23) 174 (28)
Both 27 (33) 132 (21)
Chemotherapy type, No. (%)
Cytotoxic 63 (56) 446 (60) .43
EGFR inhibitor 21 (19) 114 (15) .14
HDAC inhibitor 8 (7) 54 (7) .68
mTOR inhibitor 2 (2) 14 (2) 1.00
Bevacizumab 8 (7) 44 (6) .37
Other targeted agent 10 (9) 88 (12) .74
Radiologic
Median tumor size, mm (range)
AP 36 (18-57) 36 (14-70) .98
Transverse 43 (15-76) 45 (17-81) .08
CC 40 (20-88) 43 (16-107) .04
Median pons size, mm (range)
AP 36 (21-50) 35 (20-58) .12
Transverse 49 (31-62) 48 (22-78) .62
Extrapontine extension, No. (%) .04
Yes 78 (86) 739 (92)
No 13 (14) 60 (8)
(continued in next column)
Table 1. Results of Univariable Analyses Comparing Clinical, Radiologic, and
Histologic Characteristics of Long- and Short-Term Survivors of Diffuse
Intrinsic Pontine Glioma (continued)
Hemorrhage, No. (%) .35
Yes 11 (14) 136 (19)
No 68 (86) 588 (81)
Necrosis, No. (%) .009
Yes 20 (26) 306 (42)
No 56 (74) 424 (58)
Hydrocephalus, No. (%) 1.00
Yes 14 (18) 136 (18)
No 65 (82) 632 (82)
Tumor margin, No. (%) .14
Ill deﬁned 64 (75) 605 (82)
Well deﬁned 21 (25) 132 (18)
Ring enhancement, No. (%) .007
Yes 19 (23) 281 (38)
No 63 (77) 457 (62)
Histologic
Biopsy, No. (%) .03
Yes 38 (38) 249 (28)
No 61 (62) 652 (72)
Autopsy, No. (%) .04
Yes 11 (18) 65 (10)
No 49 (82) 597 (90)
WHO grade, No. (%) .08
2 12 (41) 40 (21)
3 9 (31) 76 (40)
4 8 (28) 73 (39)
Abbreviations: AP, anterior-posterior; CC, craniocaudal; EGFR, epidermal growth
factor receptor; HDAC, histone deacetylase; LTSs, long-term survivors; mTOR,
mammalian target of rapamycin; SIOPE, European Society for Pediatric Oncol-
ogy; STSs, short-term survivors.
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children with DIPG age , 4 years compared with older children
(13.6 v 10 months); only eight patients (61%) received RT. Although
limitations to our data precluded making conclusions about biologic
differences in this young age group, we postulate that unique mech-
anisms, such as potently oncogenicNTRK fusions described in infantile
midline high-grade gliomas,18 may underlie this observed survival
advantage.
Patients age . 10 years at diagnosis had longer median OS
(13months) and weremore likely to be LTSs. Bailey et al19 similarly
reported ﬁve LTSs (all . 9 years old) among 43 patients with
radiographically conﬁrmed DIPG. In contrast, Veldhuijzen van
Zanten et al16 reported no difference in OS between patients age
9 to 18 years versus younger patients. Although pathogenic
mechanisms, such as low-grade histology or IDH mutation may
inﬂuence survival in older patients, 78% of patients. 10 years old
in our study harbored the poor prognostic H3.3 K27M mutation.
Clinical and molecular characteristics for patients age . 18 years
(n = 13) were also similar to their younger counterparts (Appendix
Fig A3, online only).
Consistent with prior reports,1,2 the presence of symptoms
for . 24 weeks at diagnosis was strongly associated with longer
survival in univariable and multivariable analyses. CN palsy at
diagnosis predicted shorter survival in univariable but not mul-
tivariable analysis. Previous studies reporting association of CN
palsy with shorter survival included all brainstem tumors, not just
DIPG, and/or diagnosis based on computed tomography scan,
making comparison difﬁcult.20
Neoadjuvant or adjuvant systemic therapy correlated with
long-term survival in both univariable and multivariable analyses.
This ﬁnding differs from the long-standing view that systemic
therapy provides no survival beneﬁt for DIPG, a principle largely
based on small, nonrandomized clinical trials. Effective cross-
comparison of therapeutic studies for DIPG has been hindered
by wide variation in inclusion criteria, as demonstrated in studies
by Hargrave et al21 and Jansen et al22 in which only six of 29 DIPG-
speciﬁc therapeutic trials between 1984 and 2012 had comparable
eligibility. In a randomized trial, Wagner et al5 reported better
median OS in patients with DIPG treated with adjuvant chemo-
therapy after RT (11.3 months) compared with patients treated
with RT alone (9.5 months; P = .03). Similarly, others have re-
ported superior median OS with use of adjuvant or neoadjuvant
chemotherapy.4
Multivariable logistic regression demonstrated higher odds of
long-term survival with use of EGFR inhibitors (eg, geﬁtinib, erlotinib,
nimotuzumab, rindopepimut, cetuximab) or bevacizumab at di-
agnosis. A phase II study of geﬁtinib with RT in newly diagnosed
patients with DIPG noted 2-year OS of 19.6%with PFS. 36months
in three patients.23 In a biopsy-mandated phase I study of erlotinib with
RT, EGFR overexpression trended toward longer PFS (10.1 months
v 6.3 months in patients without EGFR overexpression; P = .058)
but not OS.24 Despite only modest activity of nimotuzumab in
progressive DIPG, two patients lived for 663 and 481 days from the
start of therapy.25
Despite efﬁcacy in adult GBM, bevacizumab has shown little
activity in pediatric trials for newly diagnosed26 or progressive
DIPG27 (median PFS, 2.3 months). However, in a phase I trial of
vandetanib, a selective vascular endothelial growth factor receptor
receptor 2 (VEGFR2) and EGFR inhibitor, in newly diagnosed
DIPG, Broniscer et al28 reported 2-year OS of 21.4%, and higher
levels of plasma VEGF were associated with longer PFS (P = .02).
Although numbers were too small to assess patient outcomes based
on genomically matched targeted therapy, our ﬁndings support
prospective assessment of biopsy tissue to deﬁne potential therapeutic
targets, as recently undertaken in two multi-institution, multinational
trials (ClinicalTrials.gov identiﬁers: NCT01182350 andNCT02233049).
Table 2. Results of Multivariable Cox Proportional Analysis of Clinical,
Radiologic, and Molecular Variables Predicting Survival
Variable Odds Ratio (95% CI) P
Clinical
Age, years .02
, 3 2.82 (1.06 to 10.28)
3-10 1.0
. 10 2.24 (1.27 to 3.96)
Symptom duration, weeks , .001
, 6 1.0
6-12 1.49 (0.76 to 2.92)
12-24 2.43 (1.04 to 5.75)
. 24 5.7 (2.77 to 14.54)
Cranial nerve palsy .08
Yes 0.57
No 1.0
Systemic therapy at diagnosis .01
Yes 3 (1.46 to 7.3)
No 1.0
Category of systemic therapy .14
Cytotoxic chemotherapy 1.0
Targeted chemotherapy 1.03 (0.51 to 2.09)
Both 1.84 (0.99 to 3.41)
Systemic therapy type
Cytotoxic 1.59 (0.73 to 3.45) .24
EGFR inhibitor 2.32 (1.1 to 4.82) .03
HDAC inhibitor 1.49 (0.62 to 3.6) .38
mTOR inhibitor 0.98 (0.11 to 8.66) .98
Bevacizumab 2.67 (1.09 to 6.55) .03
Other targeted agent 0.71 (0.22 to 2.28) .56
Radiologic
Tumor dimension, mm .58
AP —
Transverse 0.99 (0.96 to 1.02)
CC —
Extrapontine extension .91
Yes 0.95 (0.36 to 2.43)
No 1.0
Molecular
H3F3A mutation .04
Yes 1.0
No 1.14 (1.01 to 1.28)
HIST1H3B mutation .002
Yes 1.0
No 0.78 (0.67 to 0.91)
ACVR1 mutation .09
Yes 1
No 0.75 (0.54 to 1.03)
TP53 mutation .36
Yes 1
No 0.92 (0.76 to 1.1)
NOTE. Necrosis, enhancement, and WHO grade were excluded because .
15% of data for these variables were missing. Types of systemic therapy are not
mutually exclusive and were not excluded for multiple therapies.
Abbreviations: AP, anterior-posterior; CC, craniocaudal; EGFR, epidermal
growth factor receptor; HDAC, histone deacetylase; mTOR, mammalian target
of rapamycin.
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Janssens et al29 reported improved OS in 31 children with
DIPG who received reirradiation at ﬁrst progression (13.7 months)
compared with a matched control cohort (10.3 months) despite
similar PFS (8.2 v 7.7 months, respectively). Progression was not
deﬁned or centrally reviewed in our study; however, we noted that
the proportion of patients with recorded progression within 1 year
of diagnosis was signiﬁcantly lower among patients who underwent
reirradiation compared with those who did not, suggesting potential
clinician bias to recommend reirradiation to patients with a more
indolent disease course or potentially greater sensitivity to initial RT
in patients who ultimately received reirradiation. As postulated by
others,30 increased RT sensitivity may be a manifestation of distinct
biology. We did not report reirradiation-based outcomes given
limitations conferred by analysis of registry data; more robust
analysis of the effect of reirradiation in patients with DIPG would
be best assessed prospectively in the context of a clinical trial.
On the basis of the radiographic deﬁnition of DIPG by
Barkovich et al,31 patients with, 50% pontine involvement (n = 5)
were excluded. Similar to a prior report,5 these patients had better
median OS (20 months), and two patients were LTSs. Greater
craniocaudal tumor dimension and extrapontine extension were
associated with shorter survival; the former ﬁnding contrasts with
a report by Poussaint et al,32 in which larger tumor at diagnosis was
associated with longer survival.
As previously described,32 tumor necrosis and ring en-
hancement were associated with short-term survival in univariable
analysis. Multivariable analysis was not performed because. 15%
of data were missing for each variable, precluding comparison of
our ﬁndings to the validated multiparametric prediction model
published by Jansen et al.2
DIPG biology has been intensely studied since discovery of
ﬁrst-in-human histone mutations in 2012.15 Our ﬁndings conﬁrm
the independent association of H3.1 K27M and H3.3 K27M with
long- and short-term survival, respectively.3,15 Median OS did not
signiﬁcantly differ between histone wild-type and mutant DIPGs;
this contrasts with the report by Khuong-Quang et al15 of longer
median OS (4.59 years) for patients with histone wild-type tumors.
In univariable analysis, WHO grade did not differ between
LTSs and STSs (Table 1), but on Kaplan-Meier analysis, WHO
grade 2 was associated with longer survival (Fig 3D). In the most
recent WHO classiﬁcation of CNS tumors,33 K27M-mutant midline
gliomas are classiﬁed asWHOgrade 4 regardless of histology, making
this point less relevant. Tumors classiﬁed as primitive neuro-
ectodermal tumors (now called embryonal tumor not otherwise
speciﬁed) may represent true embryonal mimics of DIPG or result
from sampling error in the context of intratumoral heterogeneity.
Embryonal pontine tumors often demonstrate sharp margination
and eccentric location, whereas others have radiologic character-
istics indistinguishable from DIPG,34 like those excluded from our
study (Appendix Table A2, online only).
A limitation of this study is use of disease-speciﬁc registry data,
which are susceptible to enrollment bias on the part of participating
institutions (which tend to be large academic centers) and patients
or families who self-refer. Variation in standards of care between
countries and institutions may have also inﬂuenced ﬁndings.
Anonymity of registry data makes some overlap of registry patients
with those previously reported possible, biasing our ﬁndings toward
similarity with published literature because they are not completely
independent cohorts. The primary strength of this study is mandated
central review of diagnostic imaging with cross-validation by highly
experienced pediatric neuroradiologists and use of standardized case
report forms. To our knowledge, this study represents the largest,
most comprehensively annotated cohort of radiographically con-
ﬁrmed DIPGs reported, offering the most accurate rates of long- and
very long–term survival for this rare tumor. Identiﬁcation of robust
survival-associated factors in this study is vital for development of
prognostic subgroups and emphasizes patient subsets from whom
the most could be learned from analyzing pretreatment biopsy
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Fig 4. Genomic aberrations in long-term survivors of
diffuse intrinsic pontine glioma (DIPG). DIPG, International
DIPG Registry; FR, France; GER, Germany, Switzerland,
Austria; NETH, the Netherlands; OS, overall survival.
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tissue. Understanding biologic differences that confer survival advantage
in DIPG paves the road toward development of subgroup-speciﬁc
therapies that, when implemented in the context of clinical trials,
may improve outcomes for this devastating disease.
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Fig A1. Very long–term survivors of diffuse intrinsic pontine glioma in the current study comparedwith those described in the literature. Yellow highlight indicates atypical
radiologic features that would have been excluded in the current study. Bev, bevacizumab; CN, cranial nerve; DIPG, diffuse intrinsic pontine glioma; EGFR, epidermal
growth factor; GER, Germany, Switzerland, Austria; GOSH, Great Ormond Street Hospital; HDAC, histone deacetylase inhibitor; HGG, high-grade glioma; IDIPGR, In-
ternational Diffuse Intrinsic PontineGlioma Registry; IT, Italy; LFU, last follow-up; NCI, National Cancer Institute; NETH, theNetherlands; OS, overall survival; POG, Pediatric
Oncology Group; Re-RT, reirradiation; RT, radiation therapy; SIOPE, European Society for Pediatric Oncology; SJCRH, St Jude Children's Research Hospital; UK, United
Kingdom; WT, wild type.
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Fig A2. (A) Comparison of characteristics of patients who received therapy or did
not receive therapy at diagnosis. (B) Magnetic resonance images and clinical
characteristics of two long-term survivors (LTSs) of diffuse intrinsic pontine glioma
who did not receive therapy. CN, cranial nerve; GER, Germany, Switzerland,
Austria; LFU, last follow-up; NETH, the Netherlands; OS, overall survival; Re-RT,
reirradiation; RT, radiation therapy.
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Fig A3. Clinical, radiologic, and molecular characteristics of patients with diffuse
intrinsic pontine glioma age. 18 years. Bev, bevacizumab; CN, cranial nerve; DIPG,
International DIPG Registry; EGFR, epidermal growth factor; FR, France; GER,
Germany, Switzerland, Austria; HDAC, histone deacetylase inhibitor; IT, Italy; LFU,
last follow-up; OS, overall survival; Re-RT, reirradiation; RT, radiation therapy; WT,
wild type.
Table A1. Biopsies and Autopsies Performed by Country or Region
Country
No./Total No. (%)
Biopsy Autopsy
SIOPE-DIPGR
France 109/113 (96) 2/115 (2)
Germany/Switzerland/Austria 81/278 (29) 4/16 (25)
The Netherlands 29/114 (25) 10/113 (9)
Italy 17/79 (22) 0/71 (0)
Croatia 2/7 (29) 0/5 (0)
United Kingdom 7/43 (16) 0/43 (0)
IDIPGR
United States/Canada/Australia 54/372 (15) 61/376 (16)
Abbreviations: IDIPGR: International Diffuse Intrinsic Pontine Glioma Registry;
SIOPE-DIPGR, European Society for Pediatric Oncology Diffuse Intrinsic Pontine
Glioma Registry.
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Table A2. Clinical, Radiologic, and Molecular Characteristics of Patients With Primitive Neuroectodermal Tumor
Patient Age (months)
Symptom
Duration (weeks) Symptoms Treatment at Diagnosis OS (months) Source of Tissue Molecular Findings
DIPG-0051 27 Unknown Unknown RT + vorinostat 6 Biopsy WT H3.3
DIPG-0165 53 , 6 CN, pyramidal RT + vorinostat 7 Biopsy WT PDGFRA and EGFR
DIPG-0236 62 , 6 Unknown RT 5 Autopsy Mutant TP53 and NF1
Ampliﬁed MYCN
WT H3.3, H3.1, ACVR1,
PDGFRA, EGFR, ATRX,
DAXX, PIK3CA, MET,
CDKN2A/B, CCND1/2,
CDK6, PPM1D
Abbreviations: CN, cranial nerve; DIPG, International DIPG Registry; OS, overall survival; RT, radiation therapy; WT, wild type.
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